NEW YORK (GenomeWeb News) – Shares of Foundation Medicine soared in their debut on the Nasdaq Global Select Market this morning.

The Cambridge, Mass.-based cancer genomics analysis firm said after the close of the market yesterday that it had launched its initial public offering of about 5.9 million shares at $18 per share.

In early Wednesday trade, the stock was up around 80 percent at $32.31.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.